ReviewAnimal cells and systems2026
Sumoylation of cyclin and its therapeutic potential for cancer.
Review in Animal cells and systems, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The precision of the cell cycle is essential for organismal development, tissue homeostasis, and the prevention of malignancies. Cyclins and cyclin-dependent kinases (CDKs) play pivotal roles in regulating cell cycle progression. Recent studies have underscored the importance of post-translational modifications, particularly sumoylation, in modulating the functions of cyclins. Sumoylation profoundly influences the stability, localization, and activity of cyclins D and E, which are crucial for the G1/S transition and DNA replication. Dysregulation of these processes is a hallmark of various cancers, where aberrant sumoylation enhances the oncogenic potential of cyclins. This review examines how sumoylation governs cyclin dynamics, maintains cell division fidelity, and contributes to cancer progression. Moreover, advances in targeting the SUMO pathway offer new therapeutic opportunities for treating cyclin-related malignancies, positioning sumoylation-based strategies as promising tools in precision medicine. Gaining a deeper understanding of how sumoylation regulates cyclins may ultimately transform therapeutic approaches for cyclin-dependent diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.